There are three known criteria that underlie drug reimbursement decisions: therapeutic value, cost effectiveness and burden of disease. However, evidence from recent reimbursement decisions in several jurisdictions points to residual unexplained variables,_ one of which may be budget impact._ An...

Five years ago, cloud computing was one of the top emerging new technologies, nowadays it is almost common place. This rapid introduction of cloud business models in our society coincides with critical questions on the cloud’s risks, such as security and privacy. Moreover, there seems to be an...

The National Institute for Clinical Excellence has recently changed its guidelines on discounting costs and effects in economic evaluations. In common with most other regulatory bodies it now requires that health effects should be discounted at the same rate as costs. We show that the guideline...

This paper capitalizes on a first set of experiences on the application of multi-criteria decision analysis (MCDA) in seven low- and middle-income settings. It thereby reacts to a recent paper by Peacock et al., highlighting the potential of MCDA to guide policy makers in highly specific...